Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2006

View Archived Issues

EAGLE study of Axxion stent meets primary endpoint

NicOx signs new ophthalmology agreement with Pfizer

Takeda selects cardiovascular target from Lexicon alliance

Nonapprovable letter for Emezine

Nastech reacquires rights to PYY3-36 nasal spray from Merck

Applied Biosystems completes acquisition of Ambion's Research Products Division

Keryx studies KRX-0401 for refractory leukemias

Sangamo licenses use of MaxCyte's cell loading system

Evizon 40 mg safe and active in stabilizing vision in wet AMD

Ganite effective compared with Aredia in cancer-related hypercalcemia

Oral NV-52 demonstrates rapid absorption and appreciable plasma levels

Endocannabinoid-derived topical treatment for atopic dermatitis

New inhibitor of PDGFR autophosphorylation for cell-proliferative disorders

Lucentis submitted for European approval for wet AMD

Novartis seeks European approval for Exforge

Priority review for Revlimid sNDA

Novel antiinfective agents covered in recent patents

Neupro receives approvable letter for early Parkinson's disease

Monoclonal antibody induces regression of HGF-dependent tumors in mice

Recent Pfizer, Gruenenthal and AstraZeneca patents report novel analgesic agents

Recent patents report novel agents for metabolic disorders

Clinical study of pollen extract preparation in CNBP/CPPS

R-850 shows good safety and efficacy profile in actinic keratosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...